Nu­va­tion inks all-stock deal for US-Chi­na on­col­o­gy biotech An­Heart

Last year
Startups
Deals

Up­dat­ed: FDA re­jects Re­gen­eron's bis­pe­cif­ic for lym­phoma over con­fir­ma­to­ry tri­al sta­tus

Last year
FDA+

J&J's Acte­lion buy­out pays off again with ap­proval of Op­syn­vi in pul­monary ar­te­r­i­al hy­per­ten­sion

Last year
Pharma
FDA+

Es­pe­ri­on eyes new com­mer­cial push for cho­les­terol-low­er­ing drugs af­ter big FDA la­bel ex­pan­sion

Last year
Pharma
FDA+

No­vo to buy mid-stage heart fail­ure biotech Car­dior for up to $1.1B

Last year
Startups
Deals

Re­turn of the megarounds; Nvidia’s AI pitch to biotech; Bay­er’s shake­up reach­es the top; As­traZeneca buys in­to ...

Last year
Weekly

Lead House spon­sor of WuXi-linked bill to leave Con­gress ear­ly

Last year
People
China

FDA to delete 'Y­ou are not a horse' post and oth­ers in iver­mectin case set­tle­ment

Last year
Pharma
FDA+

Sen­a­tors push HHS on ‘in­ad­e­quate’ re­sponse to Change Health­care cy­ber­at­tack

Last year
FDA+
Health Tech

Why Lenz picked a re­verse merg­er in­stead of an IPO: Q&A

Last year
People
Financing

Leqem­bi au­tho­riza­tion in EU is de­layed for pro­ce­dur­al is­sues

Last year
Pharma

Seagen’s for­mer com­mer­cial chief joins the board at health­care agency minds + as­sem­bly

Last year
People
Pharma

In­tel­lia ex­its he­mo­phil­ia B pact with Re­gen­eron; Sang­amo tar­gets $24M raise

Last year
News Briefing

Nkar­ta drops a can­cer pro­gram, putting au­toim­mune front and cen­ter. Will it pay off?

Last year
R&D
Cell/Gene Tx

GSK to part ways with 'most' Bel­lus Health em­ploy­ees a year af­ter $2B buy

Last year
People
Pharma

Mei­ji Sei­ka Phar­ma to sup­ply Japan with self-am­pli­fy­ing mR­NA Covid-19 vac­cine in fall/win­ter of 2024

Last year
Nikkei Biotechnology

Novo's week­ly in­sulin se­cures CHMP thumbs-up as FDA de­ci­sion looms

Last year
Pharma

Parex­el CEO to re­tire; CAR-T mak­er Affy­Im­mune pro­motes busi­ness leader to chief ex­ec­u­tive

Last year
People
Peer Review

FDA ap­proves Ital­far­ma­co’s drug Du­vyzat for Duchenne mus­cu­lar dy­s­tro­phy

Last year
Pharma
FDA+

Glob­al AIDS pro­gram re­vived in gov­ern­ment spend­ing pack­age as oth­er health rid­ers fall off

Last year
Pharma
FDA+

Di­a­betes and weight loss drug ad­ver­tis­ing tops $1B on strength of GLP-1 brand spend­ing

Last year
Pharma
Marketing

Ken­tucky is the fourth state to al­low in­sur­ers to re­quire biosim­i­lar pre­scrip­tions be­fore brand­ed ver­sions

Last year
Pharma
FDA+

Mer­ck re­ports an­oth­er fail­ure for Keytru­da-Lyn­parza com­bo in non-small cell lung can­cer

Last year
R&D
Pharma

VML Health part­ners on new key opin­ion leader man­age­ment for bio­phar­mas

Last year
Pharma
Marketing
First page Previous page 181182183184185186187 Next page Last page
A service from the Financial Times